| Ensuring the safe and effective FDA regulation of fecal microbiota transplantation RE Sachs, CA Edelstein Journal of Law and the Biosciences 2 (2), 396-415, 2015 | 87 | 2015 |
| Prizing insurance: prescription drug insurance as innovation incentive RE Sachs Harv. JL & Tech. 30, 153, 2016 | 70 | 2016 |
| Innovation law and policy: preserving the future of personalized medicine RE Sachs UCDL Rev. 49, 1881, 2015 | 57 | 2015 |
| Delinking reimbursement RE Sachs Minn. L. Rev. 102, 2307, 2017 | 54 | 2017 |
| The Uneasy Case for Patent Law RE Sachs Mich. L. Rev. 117, 499, 2018 | 40 | 2018 |
| Encouraging new uses for old drugs RE Sachs, PB Ginsburg, DP Goldman Jama 318 (24), 2421-2422, 2017 | 39 | 2017 |
| Innovative contracting for pharmaceuticals and medicaid's best-price rule R Sachs, N Bagley, DN Lakdawalla Journal of health politics, policy and law 43 (1), 5-18, 2018 | 33 | 2018 |
| The Medicare Innovation Subsidy MA Lemley, LL Ouellette, RE Sachs NYUL Rev. 95, 75, 2020 | 32 | 2020 |
| Administering Health Innovation RE Sachs Cardozo L. Rev. 39, 1991, 2017 | 30 | 2017 |
| New innovation models in medical AI W Price, II Nicholson, RE Sachs, RS Eisenberg Wash. UL Rev. 99, 1121, 2021 | 16 | 2021 |
| Accelerated approval—taking the FDA’s concerns seriously RE Sachs, JM Donohue, SB Dusetzina New England Journal of Medicine 387 (3), 199-201, 2022 | 13 | 2022 |
| Recent trends in Medicaid spending and use of drugs with US Food and Drug Administration accelerated approval RE Sachs, KA Gavulic, JM Donohue, SB Dusetzina JAMA Health Forum 2 (10), e213177-e213177, 2021 | 13 | 2021 |
| The new model of interest group representation in patent law R Sachs Yale JL & Tech. 16, 344, 2013 | 13 | 2013 |
| Understanding the Democrats’ drug pricing package R Sachs Health Affairs Forefront, 2022 | 12 | 2022 |
| How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts: A look back at the ACA’s successes and missed opportunities at improving … R Conti, SB Dusetzina, R Sachs Health Affairs 39 (3), 445-452, 2020 | 12 | 2020 |
| Regulating Intermediate Technologies RE Sachs Yale J. on Reg. 37, 219, 2020 | 12 | 2020 |
| Step therapy’s balancing act—protecting patients while addressing high drug prices RE Sachs, MA Kyle The New England journal of medicine 386 (10), 901, 2022 | 10 | 2022 |
| Reforming reimbursement for the US Food and Drug Administration’s accelerated approval program to support state Medicaid programs RE Sachs, JM Donohue, SB Dusetzina JAMA Health Forum 3 (11), e224115-e224115, 2022 | 9 | 2022 |
| The Rhetorical Transformations and Policy Failures of Prescription Drug Pricing Reform under the Trump Administration RE Sachs Journal of health politics, policy and law 46 (6), 1053-1068, 2021 | 9 | 2021 |
| Medicare coverage of aducanumab—implications for state budgets RE Sachs, N Bagley New England Journal of Medicine 385 (22), 2019-2021, 2021 | 9 | 2021 |
